Financial Aspects of Longevity Risk Gavin Jones Gavin Jones is a Strategy Research Actuary at Swiss...
-
Upload
michael-boyd -
Category
Documents
-
view
213 -
download
0
Transcript of Financial Aspects of Longevity Risk Gavin Jones Gavin Jones is a Strategy Research Actuary at Swiss...
Financial Aspects of Longevity Risk
Gavin Jones
Gavin Jones is a Strategy Research Actuary at Swiss Re, where he focuses on mortality risks undertaken by the reinsurer's Life & Health Business Group. Prior to joining Swiss Re in November 2004, he worked as Mortality Risk Actuary at Prudential UK where, writing in a personal capacity, he co-authored 'Financial Aspects of Longevity Risk' with Stephen Richards. Gavin Jones has a PhD in mathematics from Cambridge University and is a Fellow of the Institute of Actuaries.
First international conference onlongevity and capital market solutions
18 February 2005
Cass Business School, London
Page 2
Financial aspects of longevity risk
Longevity liabilities are spread, in varying sizes, between insurers, the state and occupational schemes
UK insurers wrote GBP 7.4 billion of new annuities in 20031
UK life insurers have GBP 70 billion2
Public-sector pension schemes have GBP 580 billion3
Occupational pension schemes have GBP 762 billion4
1) Association of British Insurers, 2003 (figures exclude bulk annuities)
2) Richards and Jones, Financial aspects of longevity risk, Staple Inn Actuarial Society, 2004
3) Watson Wyatt press release, August 2004
4) Government Actuary’s Department, Eleventh Survey of Occupational pension Schemes, 2000
Page 3
Financial aspects of longevity risk
Mortality basis has a significant impact on the calculation of longevity liabilities
Male aged 60, fixed annuity at 5%
Source: Longevity in the 21st Century, Willets et al, 2004
0%
10%
20%
30%L
iab
ilit
y in
exc
ess
of
PA
(90)
-2 y
ears
PMA92umc GAD 2002
Page 4
Financial aspects of longevity risk
Longevity risk is capital intensive, difficult to hedge and contains considerable financial risks
Significant capital requirements apply to longevity risk
The duration of liabilities can be long and uncertain
Availability of reinsurance or other hedge for longevity exposure is limited
Deferred annuities are dominated by unmatchable interest rate and inflation risk
Page 5
Financial aspects of longevity risk
Longevity risk: shareholder exposure
Company name Shareholder longevity liabilities GBP million1
Prudential 3.2
L&G 11.0
BAE Systems 11.2
British Airways 11.2
Norwich Union 11.5
BT 29.1
1) Size of either (a) annuity liabilities or (b) pension scheme assets plus FRS 17 deficit. End-2003 figures
Page 6
Financial aspects of longevity risk
Insurers are subject to different regulatory considerations from corporate pension schemes
Insurers are discouraged from holding inadequate reserves (Financial Services Authority)
Company DB schemes are discouraged from holding excessive reserves (Inland Revenue)
– e.g. Maximum Funding Level for SSAPs is PA(90)-2
Disclosure of mortality bases not required of company DB schemes
Page 7
Financial aspects of longevity risk
Longevity risk carries a range of uncertainties
Basic statistical uncertainty
– for 50 (i.i.d) annuities require 10% capital to fund to 99% confidence
– 2004 Finance Act: pension schemes with fewer than 50 members must secure pensions as annuities
– lowest risk portfolios are large with limits to size of benefits
Anti-selection: impact of impaired market
Mortality trend uncertainty
Page 8
Financial aspects of longevity risk
Longevity risk: mortality improvements vs inflation
0%
2%
4%
6%
8%
10%
1982 1987 1992 1997 2002
Inflation
Male mortalityimprovementsage 70
Inflation target
Mid-cohortimprovementfactors age 70
Page 9
Financial aspects of longevity risk
Longevity risk: base mortality differentials (excluding future improvements)
Differential e 65 Years
Base case 22.5 n/a
Female > male 19.3 -3.2
High > low status 16.8 -2.5
Short > long duration 14.8 -2.0
High > low income 13.8 -1.0
South > North 12.8 -1.0
Overall n/a -9.7
Page 10
Financial aspects of longevity risk
Summary: financial impact of mortality on longevity risk
Correct base mortality (up to 25%)
Anti-selection effects (3%?)
Mortality trend (3%?)
Statistical uncertainty –size/heterogeneity of portfolio (2%?)